Filip Poelaert (@FPoelaert) profile picture

MD PhD FEBU - Urologist @ZAS_Ziekenhuis

Antwerp, Belgium
Joined May 2016
Photo by Filip Poelaert (@FPoelaert)Photo by Filip Poelaert (@FPoelaert)Photo by Filip Poelaert (@FPoelaert)Photo by Filip Poelaert (@FPoelaert)Photo by Filip Poelaert (@FPoelaert)Photo by Filip Poelaert (@FPoelaert)Photo by Filip Poelaert (@FPoelaert)
🚨 Major shift: @AmericanCancer now directly recommends routine PSA screening for #prostatecancer, moving off pure shared decision-making 🚨 @CACancerJournal 📋 Average risk: PSA every 2 yrs, ages 50-69 📋 High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69 📋 Non-Black w/ one first-degree relative dx ≥65: every 2 yrs, ages 45-69 🔬 Age-adjusted elevated = PSA ≥3.0 (ages 45-69) or ≥6.5 (70-74); repeat in 2 wks to 3 mo, then MRI and/or validated biomarker before biopsy 🛑 70-74 individualized; not recommended ≥75 or if life expectancy <10 yrs ⚠️ Still requires informed consent on benefits, limits, and harms, and departs from USPSTF’s grade C for 55-69 🎯 ACS has moved from “discuss it” to “do it” for average-risk men 50-69 and high-risk men from 45, its biggest change since 2010 🔗 doi.org/10.3322/caac.70112 @UroOnc @urotoday @UrologyTimes @PCF_Science @AmerUrological
5
112
5
201
18,350
Filip Poelaert retweeted
Introducing my En bloc HoLEP Video Library. Real cases, searchable by technique, prostate size and documented challenges. Free access, with an interface in 8 languages. Save the link below! I hope it helps with your learning curve! holep.icua.es/library/ #HoLEP #Urology
12
38
1
237
10,418
Filip Poelaert retweeted
Almost all high-income countries have a national policy recommending shared decision-making before PSA screening. We show: a) this recommendation never justified by evidence; b) best evidence is PSA screening not a preference-sensitive decision. journals.sagepub.com/eprint/…
1
10
2
17
4,755
🚨 MRI-first screening w/o contrast finds more ≥GG2 #ProstateCancer 🚨 @EurUrol 👥 759 pts randomized 📊 Biparametric MRI first vs MRI only if PSA ≥3 ⏱️ 15 min scan, no contrast ✅ csPCa detected: 4.6% vs 1.8% (RR 2.6, 95% CI 1.1-6.1) ✅ Several csPCa found in pts w/ normal PSA ⚠️ More biopsies in MRI-first arm (10.8% vs 5.2%) 🎯 A FAST⚡️ contrast-free MRI up front catches significant PCa a PSA screen might miss @PCF_Science @PCFnews @urotoday @UrologyTimes @UroOnc 🔗shorturl.at/NUI1i
1
15
36
2,683
Filip Poelaert retweeted
Generally assumed population-based PSA screening = increased overdiagnosis. But already lots of PSA testing going on. In a modeling study, we show organized screening would reduce PSA tests, overdiagnosis compared to current disorganized approach onlinelibrary.wiley.com/doi/…
3
13
38
4,550
Filip Poelaert retweeted
Original Article: Perioperative Apalutamide in High-Risk Localized Prostate Cancer (phase 3 PROTEUS trial) nej.md/3RuNe00 Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW #Oncology #Urology
48
133
37,886
🚨 177Lu-PSMA-617 to ADT + ARPI improves rPFS (PSMAddition) 🚨 @TheLancet 👥 1144 pts w/ PSMA+ metastatic APMN/S #ProstateCancer (50% de novo, 68% high-volume) 📊 Phase 3 RCT, 1:1, open-label, 169 sites, crossover allowed at progression 💊 177Lu-PSMA-617 (7.4 GBq q6w x6) + ADT/ARPI vs ADT/ARPI ⏱️ Median f/u 19.6 mo for rPFS ✅ rPFS HR 0.72 (95% CI 0.58-0.90), p=0.0021; median not reached in either arm BUT👇 ⚠️ G3+ AEs 51% vs 43%; dry mouth 46% vs 4% (all G1-2); more cytopenias and GI events ⚠️ QoL trended worse w/ RLT: time to FACT-P worsening 11.3 vs 17.1 mo (HR 1.14, CI crosses 1); gap seen mainly during treatment cycles, similar arms after week 36 🎯 RLT moves into earlier stage PCa. But we need to keep an eye on QoL @AmerUrological @UroOnc @SUO_YUO @PCFnews @urotoday @UrologyTimes @PCF_Science 🔗shorturl.at/yGNAS
31
2
60
4,999
🚨active surveillance, for #prostatecancer, now with a 25-year horizon🚨 @EUplatinum 📊 GÖTEBORG-1, screen-detected low- and intermediate-risk PCa, f/u up to 25 yrs ✅ extended data continue to support AS as safe for well-selected pts over the very long term ⚠️ intermediate-risk selection and adherence to follow-up still matter, this is screen-detected disease ⭐️PCa-specific survival at 25 yrs was 94% -99% for VLR -92% for LR -85% for Int Risk 🎯 bottom line: when we tell a pt w/with low-risk PCa that surveillance is safe, we can now point to a quarter century of trial follow-up. 🔗 shorturl.at/H2a6x #pcsm @AmerUrological @UroOnc @GGiannarini @PCFnews @PCF_Science @GabeCanales @ASPI_INTL
1
47
112
6,192
Filip Poelaert retweeted
🔥 POISE-3 Urology published in European Urology 🚨 In the largest randomized placebo-controlled #urology analysis of #TranexamicAcid (TXA), #TXA reduced major #bleeding risk by 37% (from 9.5% to 6.1%) with no clear increase in #thrombosis More at sciencedirect.com/science/ar… #EBM
2
40
3
128
21,536
Filip Poelaert retweeted
#SESAUA26 State of the Art Lecture @sanojpunnen PCa Screening Guidelines: ♦️Start: 45-50 yrs ♦️Screen q2-4 yrs if PSA < 1 ♦️Screen q1-2 yrs if PSA >1 ♦️Intervene: PSA 3-4 ♦️Stop: 70-75 yrs or life expectancy < 10 yrs @urotoday
37
2
74
5,018
Impact of 1g Tranexamic Acid on Outcomes in EEP Patients 🩸 Reduced bleeding complications with TXA (OR 0.17) ⏲ Shortest hemostasis time with TXA (p < 0.001) 📈 Higher bleeding risk on blood thinners (OR 2.93) @DocGauhar @trwherrmann @ytanidir @drabhaymahajan @doc_sarvajit @endouro @D_Castellani @steffiyuen
3
18
1
56
6,611
🌍 Global patient reported outcomes (PROs) after localized #ProstateCancer treatment 👇New data from 27,499 patients across 16 countries (TrueNTH Registry) Big predictors 🏁 Baseline function matters most 🏥 Treatment modality drives domain-specific tradeoffs 12-mo outcomes 🔴 RP → ↓ urinary continence & sexual function 📡 EBRT + ADT → ↓ bowel & hormonal function 🟢 AS → smallest functional declines Reality check ⚠️Global models explain only ~14–32% of variance 🌐 Major regional heterogeneity → one-size models fall short 🎯 Takeaway Personalized counseling needs baseline function + local context, not just treatment labels 🔗shorturl.at/bjBcf @UCLAHealthJCCC @UclaUrology @CS_Urology @CSCancerCenter @UrologyTimes @PCFnews @renalandurology @urotoday
1
9
27
2,552
Filip Poelaert retweeted
🚨 New ESMO guideline on localized & locoregional prostate cancer! annalsofoncology.org/article… 💥 Clear algorithms for diagnosis, risk stratification & treatment 🎯 Active surveillance where appropriate & escalation when needed 🤝 Multidisciplinary (evidence-based) globally aligned Good oncology isn’t about doing more…it’s about doing it right!! Congrats to @AttardLab @Ecastromarcos @stefanofanti4 @Silke_Gillessen @Prof_Nick_James @piet_ost @MarkARubin1 @ChrisSweens1 @Tilki_De @ZilliThomas @alison_tree and all the team! 👏🏼 @OncoAlert #OncoAlertAF @OncoReporte @myESMO @_SEOM
1
49
2
142
11,308
PSA for Prostate Cancer Screening: How ERSPC confirms the importance of active surveillance open.substack.com/pub/beyond…
1
1
233
🤖🆚🗡️ Robotic vs open partial nephrectomy for complex kidney tumors 👏Tested in an RCT (OpeRa trial) @Annals_Oncology 🔑🔑 Takeaways: ⚖️ 30-day complications: no significant difference (RAPN 37% vs OPN 46%) ⏱️ RAPN = longer OR + warm ischemia time 🏥 RAPN = shorter hospital stay 💊 Less opioids, less pain 😊 Better QoL through POD30 ⭐️ RAPN not clearly safer, but easier on patients in the short term — even for intermediate/high-complexity tumors 🔗shorturl.at/dUbgk @urotoday @renalandurology @UrologyTimes
3
14
43
4,602